ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO1149

Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels During Pregnancy

Session Information

  • Pediatric Nephrology - I
    October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1600 Pediatric Nephrology

Authors

  • Trachtman, Howard, NYU Langone Health, New York, New York, United States
  • Vento, Suzanne M., NYU Langone Health, New York, New York, United States
  • Gilbert, Joseph F., NYU Langone Health, New York, New York, United States
  • Koshy, Tony Thomas, NYU Langone Health, New York, New York, United States
  • Afanasyeva, Yelena, NYU Langone Health, New York, New York, United States
  • Wei, David Changli, Rush University, Chicago, Illinois, United States
  • Reiser, Jochen, Rush University Medical Center, Chicago, Illinois, United States
  • Trasande, Leonardo, NYU Langone Health, New York, New York, United States
Background

suPAR is an inflammatory mediator that has been linked to the pathogenesis of FSGS and progression of chronic kidney disease in children and adults. Overexpression of suPAR leads to reduced nephron development in preclinical models. This study was designed to measure suPAR in pregnant women to determine the range of fetal exposure to this molecule and its potential influence on antenatal human kidney growth.

Methods

Pregnant women enrolled in the Children’s Health and Environment Study (CHES) provided serum samples obtaining during 1-3 trimesters. Clinical information was obtained from the electronic health record. suPAR levels were determined by ELISA (Virogates, Copenhagen, Denmark). Data are presented as mean±SD. Results were analyzed by Pearson correlation and ANOVA.

Results

515 mothers were studied, age 31±6 yr, and racial distribution 44% Caucasian, 7% African American, 9 % Asian, and 41% other/unspecified. 46% of the women were Hispanic. 29% had completed a high school education or less and 28% had an annual income <$50,000. There were 464 livebirths, 50.4% girls. The serum suPAR levels (mean, SD, minimum, maximum) are summarized in the Table. The suPAR levels in the subgroup of women who provided more than one sample during pregnancy were closely correlated (r=0.79-0.94, P<0.0001)). The decline in serum suPAR levels from trimester 1 to 3 was highly significant (P<0.001).

Conclusion

Maternal suPAR levels are detectable throughout pregnancy but decline from trimester 1 to 3. The levels are highly correlated and steady during the course of pregnancy in an individual woman. There is more than a 10-fold range in suPAR concentration which may contribute to the biological variation in nephron number at birth. Follow-up assessment in the infants will be performed in the prospective Environmental Influences on Child Health Outcomes (ECHO) cohort study.

Serum suPAR :Levels During Pregnancy
Trimester (T)NMeanSDMinimumMaximum
T14262.860.921.0814.47
T21332.681.331.1513.65
T31712.341.000.6511.00

Funding

  • NIDDK Support